Mandate

Vinge advises Stendörren in connection with issuance of green notes and tender offer

September 13, 2024

Vinge has advised Stendörren Fastigheter AB in connection with its issuance of senior unsecured green notes in an amount of SEK 800 million (within a framework of SEK 1200 million) and its parallel tender offer in respect of its previously issued notes due 2025.

An amount corresponding to the net proceeds from the new notes will be used in accordance with Stendörren’s previously established green financing framework and to repurchase parts of Stendörren’s outstanding senior unsecured notes due 2025.

The notes are intended to be listed on the sustainable bond list of Nasdaq Stockholm. The notes have a tenor of 3.25 years and were issued with a coupon of STIBOR 3m + 290 basis points.

Nordea Bank Abp, Skandinaviska Enskilda Banken AB (publ) and Swedbank AB (publ) acted as joint bookrunners and dealer managers in the transaction.

Vinge’s team consisted of Mikael Ståhl, Lionardo Ojeda, August Ahlin and Rebecka Margolin.

Related

Vinge advises Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of Bizware

Vinge has advised the Nordic private equity firm Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of the data analytics and AI firm Bizware AB and its subsidiaries Bizware Lead AB and Bizware Nova AB.
September 11, 2025

Vinge has acted as local counsel supporting lead counsel Latham & Watkins in advising Cadence in connection with its acquisition of Hexagon’s Design & Engineering Business for approx. EUR 2.7 billion

Cadence (Nasdaq: CDNS) announced it has entered into a definitive agreement to acquire the Design & Engineering business of Hexagon AB, which includes its MSC Software business—a pioneer in engineering simulation and analysis solutions.
September 09, 2025

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025